The FEI has announced three adverse analytical findings under the FEI Anti-Doping Rules for Human Athletes (ADRHA), which are compliant with the World Anti-Doping Agency (WADA) Code.
The three athletes were all tested at the Ocala-Reddick CCI in Florida (USA), 16-20 November 2017.
Athlete/NF: Alyssa Phillips /USA (FEI ID 10047498)
Event: CCI1*, CCI2*, CIC3* - Ocala-Reddick FL (USA), 16.-20.11.2017
Prohibited Substance: Amfetamine, Canrenone
Athlete/NF: Hannah Burnett /USA (FEI ID 10007210)
Event: CCI1*, CCI2*, CIC3* - Ocala-Reddick FL (USA), 16.-20.11.2017
Prohibited Substance: Amfetamine
Athlete/NF: Jennie Brannigan /USA (FEI ID: 10013055)
Event: CCI1*, CCI2*, CIC3* - Ocala-Reddick FL (USA), 16.-20.11.2017
Prohibited Substance: Amfetamine, Methylphenidate, Ritalinic Acid
In accordance with the WADA Code, the FEI has notified WADA and the United States Anti-Doping Agency (USADA) of the positives.
The athletes have been provisionally suspended from the date of notification (21 December) until the FEI Tribunal renders a decision, but can request the lifting of the provisional suspension and ask for testing of the B sample within the next 21 days.
In order to maintain the integrity of the ongoing legal process, the FEI will not comment further on any of these cases.
Details on these cases are available here.
